National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Via Portuense, 292, 00149, Rome, Italy.
Infection. 2019 Aug;47(4):655-659. doi: 10.1007/s15010-019-01286-6. Epub 2019 Feb 26.
In endemic countries with a high level of chloroquine resistance, Plasmodium vivax malaria is associated with high morbidity and mortality. In these areas, the dihydroartemisinin-piperaquine combination resulted in clinical response, a more rapid clearance of parasitaemia, compared to chloroquine therapies, and reduction of recrudescence or reinfection.
We describe five cases of Plasmodium vivax malaria in returning travelers treated with dihydroartemisinin-piperaquine.
All patients showed the early parasite clearance and no side effects. Our preliminary results suggest that the dihydroartemisinin-piperaquine combination is effective and safe even in imported cases.
A unified treatment policy using the artemisinin combination therapy should be adopted even in non-endemic countries and larger studies are underway to support this strategy.
在氯喹耐药水平较高的流行地区，间日疟与较高的发病率和死亡率相关。在这些地区，与氯喹疗法相比，双氢青蒿素-哌喹联合疗法可带来临床应答、更快地清除寄生虫血症，并降低复发或再感染的风险。
我们描述了 5 例用双氢青蒿素-哌喹治疗的返回旅行者间日疟病例。
所有患者均表现出早期寄生虫清除且无副作用。我们的初步结果表明，即使是输入性病例，双氢青蒿素-哌喹联合疗法也是有效且安全的。
即使在非流行地区也应采用以青蒿素为基础的联合疗法的统一治疗策略，目前正在进行更大规模的研究以支持这一策略。
